NEU 0.26% $15.57 neuren pharmaceuticals limited

ACADIA earnings, page-18

  1. 5,913 Posts.
    lightbulb Created with Sketch. 17963
    From Stackhead itself, “Tim is one of Australia’s best-known small-cap share analysts and business journalists. He has more than 30 years of experience writing for major business publications. He is known for the highly-respected Criterion investment column which ran for many years in The Australian newspaper.”

    Wag, I don’t disagree with your “amateur verdict”.

    Below is a link to my views on this matter, written 9 months ago now. I was right about the $20m cap raise, but wrong about the timing and the price (it was difficult to believe that, just one month later, the company would flog its shares for almost 20% less than they were priced at the time).

    My view hasn’t changed, other than that I think ACAD could now get away with a takeover offer considerably less than the A$4.44 I hypothesized in my post.

    An “embedded” NEU was indeed an ideal strategic fit for Acadia. No no wonder the comment during the Acadia conference call last week, in reply to a question on future business development opportunities, that Acadia really liked the risk profile of the trofinetide program and that it would be happy to make a dozen more investments like trofinetide were it given the opportunity.

    https://hotcopper.com.au/threads/an...5417614/page-12?post_id=44937943#.YDy6nmhLiUk
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$15.57
Change
-0.040(0.26%)
Mkt cap ! $1.990B
Open High Low Value Volume
$15.83 $15.87 $15.20 $8.124M 524.8K

Buyers (Bids)

No. Vol. Price($)
1 64 $15.49
 

Sellers (Offers)

Price($) Vol. No.
$15.58 597 1
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.